Moonshots with Peter Diamandis

Investors should prioritize Alphabet (GOOGL) as it transitions into an AI infrastructure powerhouse, leveraging its industry-leading Cloud growth and custom TPU chips to create a dominant, vertically integrated moat. In the semiconductor space, maintain exposure to NVIDIA (NVDA) while considering Intel (INTC) as a strategic play on domestic manufacturing and national security tailwinds. Look beyond software to the "physical layer" of AI by investing in cooling systems, energy providers, and memory manufacturers like Samsung or SanDisk to capture the surge in data center demand. For private market exposure, focus on "orchestration layer" companies like Blitzy that provide autonomous enterprise solutions rather than simple model wrappers. Be cautious of OpenAI's delayed IPO (projected for 2027) and instead watch for Microsoft (MSFT) to develop in-house models as their exclusive partnership cools.

Investors should prioritize companies controlling the compute supply chain, such as data centers and specialized hardware providers, to capitalize on the massive compute shortfall expected by 2028. Eli Lilly (LLY) remains a high-conviction play as its new "triple agonist" peptide, Retatrutide, shows superior clinical results for weight loss and liver health compared to current market leaders. The investment value is shifting from pure software toward Physical AI, making humanoid robotics leaders like Tesla (TSLA), Figure AI, and 1X Technologies essential long-term holdings as they scale toward millions of units by 2030. Look for "pick and shovel" opportunities in the robotics sector, specifically in specialized insurance and maintenance services for autonomous fleets. Monitor Colossal Biosciences and related synthetic biology firms for breakthroughs in CRISPR technology, which will likely yield high-value applications in human healthcare and agriculture by 2028.

Investors should prioritize Google (GOOGL) for its unique vertical integration, as it designs proprietary TPU chips while simultaneously securing nearly one million NVIDIA GPUs to build the world’s largest AI cloud infrastructure. TSMC (TSM) remains the essential "bottleneck" play, as every major AI developer is entirely dependent on their fabrication capacity to meet surging hardware demand. For exposure to the private AI boom, look for secondary market opportunities in Anthropic, which is seeing massive revenue velocity and multi-billion dollar backing from Amazon and Google. The energy sector is a critical secondary play, specifically Nuclear and Small Modular Reactors (SMRs), which are required to power the next generation of "Gigawatt" data centers. In healthcare, Moderna (MRNA) is a high-conviction leader as AI-driven drug discovery transforms biology into a scalable engineering problem, evidenced by recent breakthroughs in mRNA cancer trials.

Investors should focus on GLP-1 leaders like Novo Nordisk (NVO) and Eli Lilly (LLY) as these drugs expand into massive heart and brain health markets beyond simple weight loss. Monitor clinical trial results from Life Biosciences regarding their ER100 gene therapy, which aims to reverse vision loss and cellular aging. For cardiovascular health, prioritize companies developing PCSK9 inhibitors as superior alternatives to statins for reversing plaque buildup. Look for AI-driven biotech startups that utilize transcriptomic data and agentic systems like Cadence to accelerate drug discovery timelines. When evaluating early-stage longevity investments, ensure the company has a high-conviction team and enough capital runway to survive the transition from academic research to clinical trials.

Investors should closely monitor Life Biosciences as it initiates human clinical trials for OSK gene therapy, targeting glaucoma and blindness with data expected by 2026. While gene therapies are currently high-cost, the most scalable opportunity lies in AI-driven small molecules (pills) that aim to mimic age-reversal effects for a mass-market audience. Watch for the "cocktail" of longevity molecules entering human trials via the Healthspan XPRIZE within the next few months as a major catalyst for the sector. In the consumer health space, there is growing demand for NMN, Resveratrol, and Nattokinase, the latter of which is being studied for its potential to reverse arterial plaque. For diversified exposure, focus on the Bio-IT sector, where Artificial Intelligence is significantly accelerating the timeline and reducing the cost of drug discovery for age-related diseases.

Investors should reduce exposure to traditional SaaS "wrappers" like Adobe (ADBE) and Figma, as frontier labs like Anthropic are now integrating these design and coding capabilities directly into their AI models. Keep a close watch on OpenAI for a potential IPO in late 2024 or 2025, as the company aggressively pivots from research toward enterprise profitability and "AI-native" professional workflows. Monitor the SpaceX and XAI ecosystem for a massive $60 billion acquisition of Cursor, signaling that AI-driven code generation is the primary high-value frontier for achieving AGI. Maintain long-term positions in data center infrastructure and U.S. Robotics, as private capital expenditure in these sectors is currently outpacing historic government programs like the Apollo mission. To hedge against geopolitical "system shocks," diversify away from semiconductor reliance on the Middle East, as a conflict in the Strait of Hormuz could cripple global chip manufacturing by cutting off critical supplies of helium and neon.

Investors should monitor Amazon (AMZN) and Apple (AAPL) as they leverage the Globalstar acquisition to challenge SpaceX in the "Direct-to-Cell" satellite market. Focus on companies holding S-band spectrum licenses, as these assets are becoming high-value acquisition targets for global mobile connectivity. In the AI sector, prioritize Anthropic’s Claude Opus 4.7 for enterprise workflow automation, specifically for its ability to analyze complex corporate documents and PDFs via expanded vision capabilities. Due to increasing data center bans in states like Maine, look for geographic arbitrage opportunities in pro-AI regions like New Hampshire and Texas that offer a "Right to Compute." Finally, consider exposure to modular nuclear or off-grid energy solutions, as data centers are increasingly forced to bypass the traditional power grid to meet massive energy demands.

Investors should prioritize NVIDIA (NVDA) as the essential "picks and shovels" play, as massive hardware spending by AI labs continues to drive corporate revenue gains. In the private markets, Anthropic is currently seeing triple the investor demand of OpenAI, making it the high-conviction "pure-play" competitor to watch for enterprise AI growth. Monitor the OpenAI fraud trial beginning April 27th, as any court-ordered restructuring or leadership changes involving Sam Altman could significantly devalue private holdings. For exposure to AI-driven drug discovery, look toward Eli Lilly (LLY) and its partnerships with AI-first firms like Insilico Medicine to capitalize on faster clinical trial success rates. Finally, Bitcoin (BTC) remains a high-conviction "hardened" asset for long-term holders, with major institutional buyers like MicroStrategy continuing multi-billion dollar accumulations despite future quantum computing concerns.

Prepare for a generational investment opportunity in SpaceX, which is targeting a $2 trillion IPO valuation driven by the massive profitability of Starlink and a 100% year-over-year revenue growth rate. Monitor secondary markets for Anthropic, as it has overtaken OpenAI in annual revenue and is positioned as the dominant enterprise AI leader ahead of a potential 2026 IPO. Consider Intel (INTC) as a strategic turnaround play due to its $25 billion "TerraFab" partnership with XAI, which aims to move leading-edge chip manufacturing to the U.S. and reduce dependency on TSMC. Investors should pivot away from traditional luxury commodities like De Beers diamonds, as lab-grown technology has triggered an 80% price collapse and destroyed the scarcity model. Look for emerging opportunities in Orbital Data Centers and Solar Robotics, which solve the terrestrial power and equipment shortages currently delaying 50% of land-based AI projects.

Investors should monitor Colossal Biosciences as a foundational platform play in synthetic biology, utilizing AI to transform genetic engineering into a scalable industrial software model. While the company is currently private, its spin-out Breaking offers a high-conviction opportunity in the "circular economy" by using engineered enzymes to fully eliminate plastic waste. Significant revenue potential exists in Genetic Biocontrol, a $5.4 trillion market where biological tools are replacing toxic chemicals to manage invasive species for government contracts. The company’s acquisition of Viogen provides immediate cash flow through high-efficiency animal cloning, while its breakthroughs in IVF tech and artificial wombs represent massive licensing opportunities in human healthcare. Treat this sector as the next trillion-dollar frontier, where "de-extinction" serves as the R&D catalyst for immediate applications in agriculture, medicine, and environmental remediation.